Biological Aging in People Losing Weight With Semaglutide or Tirzepatide
Looks at whether weight-loss medicines change a measure of biological age in adults.
Plain-language title generated from the registry record
Registry title: Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
Key facts
- Where
- Singapore, SingaporeSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 89 years old?
Source: NCT07444073, who can take part
Where in Singapore
- National University of SingaporeSingapore, SingaporeNo longer taking part
- NOVI Health (T3 Health PTE LTD)Singapore, SingaporeNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University of Singapore
- Trial code
- NCT07444073
- Record updated
- 1 July 2026
- Original description
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.Read full original descriptionShow less
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
Inclusion: Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program; BMI of ≥ 30 kg/m2 (obesity); OR; BMI of ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Exclusion: On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months; Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes; Active cancer on chemotherapy or immunotherapy; Known hypersensitivity or contraindications to GLP-1 RAs; Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance; Pregnancy or lactation; Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.